Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

RADIOPHARMACEUTICALS - A US AND EUROPEAN MARKET REPORT   

Research Abstract

This report analyzes the US and the European markets for Radiopharmaceuticals in US$ Million by the following Product Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 65 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bio-Nucleonics, Inc., Bracco Diagnostics, Inc., Cardinal Health, Inc., Cellectar, LLC., Cell Therapeutics, Inc., Covidien Imaging Solutions, EUSA Pharma (Europe) Ltd., Jubilant DraxImage Inc., GE Healthcare Limited, GlaxoSmithKline Plc, IBA Group, Immunomedics, Inc., Lantheus Medical Imaging, Inc, Nordion, Molecular Insight Pharmaceuticals, Inc., Novelos Therapeutics Inc., Peregrine Pharmaceuticals, Inc., PETNET Pharmaceuticals, Inc., Pharmalucence, Inc., Spectrum Pharmaceuticals, Inc., and Triad Isotopes, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1889
Price : $4500
Companies : 65
Pages : 373
Date : October 2011
Market Data Tables : 92
Status: * New Report

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  RADIOPHARMACEUTICALS (Complete Report) Pages : 373   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.....I-14 $295  
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   A. Diagnostic Radiopharmaceuticals.....I-4
B. Therapeutic Radiopharmaceuticals.....I-4
  
  2. INDUSTRY OVERVIEW.....II-511 $950  
   A Quick Primer.....II-5
Market Scenario: A Review.....II-5
Recession Impact in Retrospect.....II-5
1$100
   Outlook.....II-61$100
   Key Market Trends.....II-7
Continuous Battle Against Cancer: A Key Driver for Growth.....II-7
Cancer Statistics: A Grim Prognosis.....II-7
Business Case for Radiopharmaceuticals Exemplified.....II-7
Development of Newer Diagnostic Agents to Boost Growth.....II-7
1$100
   Emergence of Radioisotope Based Personalized Therapy.....II-8
Demographics & New Applications Offer Opportunities On a Platter.....II-8
Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance.....II-8
1$100
   Widespread Awareness Among Practitioners & Patients: The Need of the Hour.....II-9
Expansion of Molecular Imaging Platform is Key to Future Growth.....II-9
Molecular Imaging Agents: A Noteworthy Breakthrough.....II-9
1$100
   Growing Demand for PET to Drive Up Demand.....II-10
Introduction of SPECT/CT & PET/CT: Double Edged Weapons for Growth.....II-10
1$100
   Manufacturers Quick to Take Cue.....II-11
Promising Developments in Therapeutic Radiopharmaceuticals Underway.....II-11
1$100
   Targeted Peptides & Alpha Emitters: The New Frontiers of Therapeutic
  Radiopharmaceuticals.....II-12
International Collaborations Give a Thumbs Up to Drug Development.....II-12
Market Challenges.....II-12
High Costs of Drug Development Piques Manufacturers.....II-12
1$100
   Supply Shortages: A Niggling Cause of Concern.....II-13 1$100
   Table 1: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Weekly Demand by Region (includes corresponding Graph/Chart).....II-14

Table 2: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Production by Reactor (includes corresponding Graph/Chart).....II-14
Price Sensitivity & Competition from Alternatives Limit Market Potential.....II-14
1$350
   Lack of Dosage Standards for Pediatric Patients’ Limits Radiopharmaceutical
  Efficacy.....II-15
Unfounded Fears of Radiation Exposure Hinder Growth.....II-15
Bottlenecks in Developing Markets.....II-15
1$100
  3. PRODUCT OVERVIEW.....II-1612 $950  
   Nuclear Medicine: A Prelude.....II-16
Radiopharmaceuticals: A Definition.....II-16
Mechanism of Action.....II-16
1$100
   Application of Radiopharmaceuticals.....II-17
Classification of Radiopharmaceuticals.....II-17
Diagnostic Radiopharmaceuticals.....II-17
1$100
   Commonly Used Diagnostic Radiopharmaceutical Agents.....II-18
Major Isotopes and their Diagnostic Applications.....II-18
1$100
   Advantages.....II-19
Classification.....II-19
1$100
   Fluorodeoxy Glucose (FDG): A Rapidly Growing Diagnostic Radiopharmaceutical.....II-20
Molecular Imaging Modalities In Radiopharmaceutical Diagnostics.....II-20
Planar Imaging.....II-20
PET: A Prime Growth Driver for FDG.....II-20
1$100
   Advantages.....II-21
Applications of PET.....II-21
1$100
   Commonly used Radioisotopes in PET Scans.....II-22
Major PET Isotopes and their Applications.....II-22
1$100
   Single Photon Emission Computed Tomography (SPECT).....II-23
Applications of SPECT.....II-23
1$100
   Commonly used Radioisotopes in SPECT Scans.....II-24
Therapeutic Radiopharmaceuticals.....II-24
Characteristics of Therapeutic Radiopharmaceuticals.....II-24
1$100
   Commonly used Therapeutic Agents.....II-25
Major Isotopes and their Therapeutic Applications.....II-25
Radiopharmaceuticals for Thyroid Therapy.....II-25
Radiopharmaceuticals for Cancer Therapy.....II-25
1$100
   Radiopharmaceuticals for Radiosynoviorthesis Therapy.....II-26
Radiopharmaceuticals for Bone Pain Palliation Therapy.....II-26
Radiopharmacy: A Key Link in the Distribution Chain.....II-26
1$100
   Table 3: US Radiopharmacies Market (2010): Percentage Share Breakdown of SPECT Doses Sold by Company (includes corresponding Graph/Chart).....II-271$350
  4. PRODUCT INNOVATIONS/INTRODUCTIONS.....II-283 $295  
   Positron to Launch PosiRx.....II-28
Positron to Develop Indium Oxine.....II-28
GE Healthcare Enhances Radiopharmaceuticals Product Portfolio.....II-28
1$100
   IBA Molecular Obtains Positive Opinion to Market Dopacis in Europe.....II-29
Bhabha Atomic Research Centre Develops Radiopharmaceuticals for Cancer
  Treatment.....II-29
1$100
   Medrad Mounts Intego™ PET Infusion System at UPMC.....II-30
IBA Molecular Announces the Launch of Cyclone ® 18 Twin.....II-30
Immunomedics Announces Pre-Clinical Results for its Combination
  Radioimmunotherapy.....II-30
Molecular Insight Develops New Radioiodinated Molecules.....II-30
Immunomedics Develops New Antibody for Radioimmunotherapy.....II-30
1$100
  5. RECENT INDUSTRY ACTIVITY.....II-3122 $1450  
   Novelos Therapeutics Pockets Cellectar Inc.....II-31
Southern Research Institute Inks Agreement with Biomedical Research Foundation.....II-31
1$100
   IBA Acquires Minority Stake in PET Net Solutions.....II-32
Covidien Enters into Agreement with IAE POLATOM.....II-32
Dalat Nuclear Research Institute Inks Agreement with Probactive Biotech.....II-32
1$100
   Principio Wins Licensing Agreement from Johns Hopkins Sidney Kimmel Comprehensive
  Cancer Center.....II-33
Covidien Inks Definitive Agreement with Triad Isotopes.....II-33
Eli Lilly Inks Merger Agreement with Avid Radiopharmaceuticals.....II-33
Lumiphore Inks Agreement with Algeta.....II-33
1$100
   IBA Renews Contract with Servicio Andaluz de Salud.....II-34
Lumiphore and Algeta Ink Partnership Agreement.....II-34
1$100
   Positron and Covidien Ink Agreement.....II-35
PETNET Solutions Expands PET Radiopharmaceutical Network.....II-35
Triad Isotopes Acquires Radiopharmacy Network of Covidien.....II-35
1$100
   Principio Receives Exclusive Technological Development License from Hopkins Sidney
  Kimmel Comprehensive Cancer Center.....II-36
PETNET Solutions Renews Supply Agreement with Paul Strickland Scanner Centre.....II-36
IBA Molecular Obtains Marketing Approval for Filtracis Radiopharmaceutical Kit.....II-36
DHA Inks MoU with DCD.....II-36
1$100
   Algeta Signs Agreement with Bayer.....II-37
TAEK to Establish Proton Accelerator Facility.....II-37
Antisoma Collaborates with Bryan Oncor.....II-37
1$100
   Karpov Institute Enters into Collaboration with MDS Nordion.....II-38
MDS Nordion Establishes Glucotrace Facility.....II-38
Draximage Inks Agreement with Guerbet.....II-38
1$100
   Eczacybathorny-Monrol Collaborates with IBA.....II-39
Safran Obtains EU Nod for GEHP Take Over.....II-39
Siemens Healthcare Signs Agreement with Calypso Medical.....II-39
1$100
   IBA Molecular to Purchase Interest in BMI.....II-40
Molecular Insight Signs Agreement with BioMedica Life Sciences.....II-40
Bayer Schering Signs Agreement with Algeta.....II-40
1$100
   IBA Inks Agreement with Aposense.....II-41
Draxis Receives Approval from Health Canada for Generic Sestamibi.....II-41
Cyclopharm and Alfred Health Solutions Form Joint Venture.....II-41
1$100
   Guerbet Inks Distribution Agreement with Draximage.....II-42
Ion Beam Applications Collaborates with Eczacibasi-Monrol Nuclear Products.....II-42
1$100
   Positron Concludes Dose Shield Acquisition.....II-43
Positron Licenses NuView to Sell Imaging Technologies and Dose Dispensing
  Devices.....II-43
Bracco Imaging, Marillion Pharmaceuticals to Develop Novel Cancer Treatment.....II-43
EUSA Pharma Concludes Cytogen Acquisition.....II-43
AMIC, CRS to Co-Produce Indium-111.....II-43
1$100
   AMIC, MU Partner to Produce Radioisotopes.....II-44
Bracco, Lantheus to Co-Promote CardioGen-82®.....II-44
Cell Therapeutics Submits sBLA for Use of Zevalin® in First-Line Therapy.....II-44
ANSTO, Siemens Ink $10m Partnership Deal.....II-44
Covidien Gets FDA Nod for Generic Myocardial Perfusion Imaging Kit.....II-44
1$100
   Neoprobe, Draximage Collaborate Over Lymphoseek Distribution.....II-45
GE Healthcare Gets FDA Nod For New PET/CT Scanner.....II-45
GE Healthcare, Gamma Medica-Ideas Ink Distribution Deal.....II-45
CIS-US Receives FDA Approval for Generic Choletec® Kit.....II-45
Cellectar Obtains Funds for Clinical Trials.....II-45
Lantheus Medical Completes Phase I Study Of Novel PET Imaging Tracer.....II-45
1$100
   GE Healthcare, Cardinal Health Partner for Myoview™ Imaging Agent.....II-46
Avista Capital Partners Acquires Medical Imaging Unit of Bristol-Myers.....II-46
Siemens Healthcare Opens Two Radiopharmacies in US.....II-46
Cardinal Health Plans to Offer Services to Support PET Clinical Trials.....II-46
1$100
   MEDRAD Associates with PETNET to Ingeniously Deliver FDG.....II-47
Triad Isotopes to Build Four Nuclear Pharmacies.....II-47
AREVA, NCI to Develop Cancer-fighting Radiopharmaceuticals.....II-47
NuView Signs Agreement with California University.....II-47
NuView Inks Exclusive Agreement with Philadelphia’s Jefferson University.....II-47
1$100
   University of Missouri Health Care Enters Sole-Source Supply Contract with Mid-America
  Isotopes.....II-48
Cardinal Health Expands Manufacturing Capabilities for PET Imaging Agents.....II-48
Jubilant Completes Draxis Acquisition.....II-48
Atomic Energy Closes Two Reactors.....II-48
1$100
   IBA Plans to Acquire CIS BIO.....II-49
Ion Beam Announces Closure of TAEK Financing.....II-49
IBA Receives Approval for New Radiopharmaceutical Production Facility in UK.....II-49
WILEX AG Signs Licensing and Marketing Deal with Ion Beam.....II-49
1$100
   Ion Beam Partners with Lantheus to Distribute Neurolite®, Cardiolite® in
  Europe.....II-50
EIS Eczacibasi to Acquire 50 Percent Stake in Monrol.....II-50
Siemens to Set up Multiple Radiopharmaceutical Facilities in India.....II-50
1$100
   Siemens Plans to Establish Its First Molecular Imaging Centre in India.....II-51
Ion Beam, Hae Dong Expands South Korea’s PET Radiopharmaceutical Market.....II-51
Bayer and FutureChem Enter Radiolabeling Technology Licensing Agreement.....II-51
1$100
   Cyclopharm Signs Agreement to Establish PET Radiopharmacy.....II-52
R2 Solucoes to Produce FGD-18, Radiological Diagnostics.....II-52
1$100
  6. FOCUS ON SELECT PLAYERS.....II-538 $595  
   Actinium Pharmaceuticals, Inc. (US).....II-53
Advanced Medical Isotope Corporation (US).....II-53
Alseres Pharmaceuticals, Inc (US).....II-53
1$100
   Bayer HealthCare Pharmaceuticals (US).....II-54
Bio-Nucleonics, Inc. (US).....II-54
Bracco Diagnostics, Inc. (US).....II-54
1$100
   Cardinal Health, Inc (US).....II-55
Covidien Imaging Solutions (US).....II-55
EUSA Pharma (Europe) Ltd. (UK).....II-55
Jubilant DraxImage Inc. (Canada).....II-55
1$100
   GE Healthcare Limited (UK).....II-56
GlaxoSmithKline Plc (UK).....II-56
IBA Group (US).....II-56
1$100
   Immunomedics, Inc. (US).....II-57
Lantheus Medical Imaging, Inc (US).....II-57
Nordion (Canada).....II-57
1$100
   Molecular Insight Pharmaceuticals, Inc. (US).....II-58
Novelos Therapeutics Inc (US).....II-58
Peregrine Pharmaceuticals, Inc. (US).....II-58
1$100
   PETNET Pharmaceuticals, Inc. (US).....II-59
Pharmalucence, Inc. (US).....II-59
Spectrum Pharmaceuticals, Inc. (USA).....II-59
Triad Isotopes, Inc. (US).....II-59
2$200
  7. GLOBAL MARKET PERSPECTIVE.....II-61   
   Table 4: World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-611$350
   Table 5: World Historic Review for Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-621$350
   Table 6: World 15-Year Perspective for Radiopharmaceuticals by Geographic Region – Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-631$350
   Table 7: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-641$350
   Table 8: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-651$350
   Table 9: World 15-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region – Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-661$350
   Table 10: World Recent Past, Current & Future Analysis for Therapeutic Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-671$350
   Table 11: World Historic Review for Therapeutic Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-681$350
   Table 12: World 15-Year Perspective for Therapeutic Radiopharmaceuticals by Geographic Region – Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-691$350
  8. THE UNITED STATES.....II-7039 $3850  
   A. Market Analysis.....II-70
Outlook.....II-70
Industry Structure.....II-70
Production Scenario.....II-70
Dependence On Imports.....II-70
1$100
   Regulatory Scenario.....II-71
Thorny Regulations Dampen Down New Product Development.....II-71
1$100
   FDA’s Antidote.....II-72
Radiopharmaceutical Reimbursement in the US: Who’s Under the Umbrella.....II-72
Diagnostic Radiopharmaceuticals Bundled As Supplies Under Medicare
  Reimbursements.....II-72
CMS Proposed Packaging of Zevalin & Bexxar into Diagnostic Radiopharmaceuticals
  Raises Eyebrows.....II-72
1$100
   Implications.....II-73
Recommendations.....II-73
1$100
   Changes in Medicare Reimbursements Vetoed.....II-74
CMS Proposes New HOPPS Guidelines for 2012.....II-74
(i) Reimbursement Rates for Nuclear Cardiology Procedures:.....II-74
1$100
   (ii) Reimbursement Rates for Radiopharmaceuticals.....II-75
HOPPS Final Rule for 2011.....II-75
(i) Reimbursement Rates for PET Imaging.....II-75
1$100
   (ii) Reimbursement Rates for Radiopharmaceuticals.....II-76
HOPPS Guidelines for 2008.....II-76
(i) Bundling Radiology Drugs and Services.....II-76
1$100
   (ii) Payment for Therapeutic Radiopharmaceuticals.....II-771$100
   (iii) PET/CT scans.....II-78
(IV) Cardiac CT and Coronary CTA Procedures.....II-78
(v) Conversion factor.....II-78
Reimbursement Issues for PET.....II-78
1$100
   PET Clinical Applications Reimbursed by CMS as of March 2008.....II-79
Deficit Reduction Act (DRA) 2005: Creating a Storm in a Teacup.....II-79
1$100
   Impact of the DRA On Outpatient Imaging Centers: An Evaluation.....II-801$100
   Market Overview.....II-81
Sanguine Growth On Cards.....II-81
Expanding Diagnostic Applications Will Stimulate Future Growth.....II-81
1$100
   Nuclear Cardiology Products Drive Up Diagnostic Radiopharmaceuticals Market.....II-82
Cardiovascular Imaging To Lead Volume Growth.....II-82
Cardiolite Loses Market Share to Generics.....II-82
1$100
   Table 13: US Diagnostic Radiopharmaceutical Agents Market (2010): Percentage Share Breakdown of Procedure Volume by Imaging Procedure - SPECT and PET (includes corresponding Graph/Chart).....II-83

Table 14: US Market for Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart).....II-83
1$350
   Table 15: US Market for Cardiology Diagnostic Radiopharmaceuticals (2010): Percentage Share Breakdown of SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume by Imaging Agent - Cardiolite, Myoview, Thallium, and Sestamibi (includes corresponding Graph/Chart).....II-84
New Oncology, Neurology Agents to Boost Diagnostic Radiopharmaceuticals
  Market.....II-84
1$350
   Table 16: US Market for Non-Cardiology Diagnostic Radiopharmaceuticals Agents (2010): Percentage Share Breakdown of Value Sales for Oncology and Non-Oncology Applications (includes corresponding Graph/Chart).....II-85
Installed Base of SPECT Scanners.....II-85
Table 17: Diagnostic Radiopharmaceutical Market in North America: Installed Base for SPECT and SPECT/CT Scanners in Units for Years 2006, 2008, 2010, 2012 & 2014 (includes corresponding Graph/Chart).....II-85
1$350
   Installed Pet Scanners in US.....II-86
US FDG Market.....II-86
Table 18: US FDG Market (2010): Percentage Share Breakdown of Procedure Volume by Procedure Type – Oncology, Neurology and Cardiology (includes corresponding Graph/Chart).....II-86
1$350
   Focused R&D Efforts will Fuel Therapeutic Radiopharmaceuticals Market.....II-87
Market Share Statistics.....II-87
Table 19: US Market for Diagnostics Radiopharmaceuticals Agents (2010): Percentage Market Share Breakdown of Leading Players (includes corresponding Graph/Chart).....II-87
1$350
   Table 20: US Market for Therapeutic Radiopharmaceuticals (2010): Percentage Share Breakdown of Value Sales by Key Radiotherapeutics - Bone Palliation, Non-Hodgkin's Lymphoma, Hyperthyroidism /Thyroid Cancer and Others (includes corresponding Graph/Chart).....II-88

Table 21: US Market for Therapeutic Radiopharmaceutical Agents (2010): Percentage Market Share Breakdown of Leading Players (includes corresponding Graph/Chart).....II-88

Table 22: US Market for Radiopharmaceutical Bone Palliation Procedures (2010): Percentage Share Breakdown by Key Radiotherapeutics - Metastron, Quadramet and Sr-89 (includes corresponding Graph/Chart).....II-88
1$350
   Table 23: Radiopharmacy Market in the US (2010): Percentage Breakdown of Revenues Generated by General Radiopharmacies and FDG Radiopharmacies (includes corresponding Graph/Chart).....II-89
Product Launches.....II-89
2$550
   Strategic Corporate Developments.....II-918$500
   Select Players.....II-997$450
   B. Market Analytics.....II-106
Table 24: US Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-106
1$350
   Table 25: US Historic Review for Radiopharmaceuticals for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1071$350
   Table 26: US 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1081$350
  9. CANADA.....II-1095 $950  
   A. Market Analysis.....II-109
Outlook.....II-109
Strategic Corporate Developments.....II-109
1$100
   Select Players.....II-1101$100
   B. Market Analytics.....II-111
Table 27: Canadian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-111
1$350
   Table 28: Canadian Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1121$350
   Table 29: Canadian 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1131$350
  10. JAPAN.....II-1143 $950  
   Market Analysis.....II-114
Table 30: Japanese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-114
1$350
   Table 31: Japanese Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1151$350
   Table 32: Japanese 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1161$350
  11. EUROPE.....II-1178 $2450  
   A. Market Analysis.....II-117
Outlook.....II-117
Competitive Scenario.....II-117
Key Statistics.....II-117
Table 33: European Radiopharmaceuticals Market (2010): Percentage Share Breakdown of Revenues by Company (includes corresponding Graph/Chart).....II-117
1$350
   Table 34: European Diagnostic Radiopharmaceuticals Market (2012): Percentage Share Breakdown of Value Sales by Imaging Modalities - SPECT and PET (includes corresponding Graph/Chart).....II-118
Market Trends.....II-118
New Applications and Products Augur Good Market Prospects.....II-118
Increasing PET and PET/CT Applications Will Kindle Growth.....II-118
1$350
   B. Market Analytics.....II-119
Table 35: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-119
1$350
   Table 36: European Historic Review for Radiopharmaceuticals by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1201$350
   Table 37: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1211$350
   Table 38: European Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1221$350
   Table 39: European 15-Year Perspective for Radiopharmaceuticals by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1231$350
   Table 40: European 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1241$350
  11a. FRANCE.....II-1254 $950  
   A. Market Analysis.....II-125
Outlook.....II-125
Strategic Corporate Development.....II-125
1$100
   B. Market Analytics.....II-126
Table 41: French Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-126
1$350
   Table 42: French Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1271$350
   Table 43: French 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1281$350
  11b. GERMANY.....II-1294 $950  
   A. Market Analysis.....II-129
Outlook.....II-129
Strategic Corporate Development.....II-129
1$100
   B. Market Analytics.....II-130
Table 44: German Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-130
1$350
   Table 45: German Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1311$350
   Table 46: German 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1321$350
  11c. ITALY.....II-1333 $950  
   A. Market Analysis.....II-133
Outlook.....II-133
B. Market Analytics.....II-133
Table 47: Italian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-133
1$350
   Table 48: Italian Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1341$350
   Table 49: Italian 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1351$350
  11d. THE UNITED KINGDOM.....II-1365 $950  
   A. Market Analysis.....II-136
Outlook.....II-136
Market Overview.....II-136
Strategic Corporate Developments.....II-136
1$100
   Select Players.....II-1371$100
   B. Market Analytics.....II-138
Table 50: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-138
1$350
   Table 51: UK Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1391$350
   Table 52: UK 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1401$350
  11e. SPAIN.....II-1413 $950  
   Market Analysis.....II-141
Table 53: Spanish Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-141
1$350
   Table 54: Spanish Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1421$350
   Table 55: Spanish 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1431$350
  11f. REST OF EUROPE.....II-14413 $1450  
   A. Market Analysis.....II-144
Outlook.....II-144
Market Overview.....II-144
Product Launches.....II-144
1$100
   Strategic Corporate Developments.....II-1459$550
   B. Market Analytics.....II-154
Table 56: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-154
1$350
   Table 57: Rest of Europe Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1551$350
   Table 58: Rest of Europe 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1561$350
  12. ASIA-PACIFIC.....II-1577 $950  
   A. Market Analysis.....II-157
Outlook.....II-157
Product Launch.....II-157
Strategic Corporate Developments.....II-157
4$400
   B. Market Analytics.....II-161
Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-161
1$350
   Table 60: Asia-Pacific Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1621$350
   Table 61: Asia-Pacific 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1631$350
  13. REST OF WORLD.....II-1644 $950  
   A. Market Analysis.....II-164
Outlook.....II-164
Strategic Corporate Developments.....II-164
1$100
   B. Market Analytics.....II-165
Table 62: Rest of World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-165
1$350
   Table 63: Rest of World Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1661$350
   Table 64: Rest of World 15-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1671$350
COMPETITION 193$995
  
Total Companies Profiled: 65 (including Divisions/Subsidiaries - 79)

Region/Country                 Players


The United States                 40    
Canada                             3
Japan                              1
Europe                            27 
     France                        1
     Germany                       6
     The United Kingdom            4
     Italy                         2
     Spain                         1
     Rest of Europe               13 
Asia-Pacific (Excluding Japan)     6
Africa                             1
Middle-East                        1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign